Familial Hypercholesterolemia - Homozygous research hub

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

This study is looking at a new medicine called inclisiran for children aged 2 to 11 with a severe type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). The aim is to see if it's safe, well-tolerated, and helps lower their cholesterol levels.